# IBRANCE® (palbociclib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/palbociclib

> The FDA approved IBRANCE® (palbociclib), sponsored by PFIZER INC (PFE), on November 1, 2019.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | IBRANCE® (palbociclib) |
| Codes |  |
| Sponsor | PFIZER INC (PFE) https://sec-api.dev/companies/pfe/catalysts |
| Indications | Locally Advanced or Metastatic ER+ HER2- Breast Cancer, [Breast Cancer](https://sec-api.dev/indications/breast-cancer) |
| Modality | small_molecule |
| FDA designations | none disclosed |

## Timeline

### November 1, 2019: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA212436 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20191101, review_priority STANDARD; sponsor_name PFIZER; product IBRANCE (PALBOCICLIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212436%22

### December 13, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA212436 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20221213, review_priority STANDARD; sponsor_name PFIZER; product IBRANCE (PALBOCICLIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212436%22
- openFDA Drugs@FDA: "NDA207103 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20221213, review_priority STANDARD; sponsor_name PFIZER; product IBRANCE (PALBOCICLIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207103%22

### September 6, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA212436 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20230906, review_priority STANDARD; sponsor_name PFIZER; product IBRANCE (PALBOCICLIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212436%22
- openFDA Drugs@FDA: "NDA207103 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20230906, review_priority STANDARD; sponsor_name PFIZER; product IBRANCE (PALBOCICLIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207103%22

### April 23, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA212436 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20250423, review_priority STANDARD; sponsor_name PFIZER; product IBRANCE (PALBOCICLIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212436%22
- openFDA Drugs@FDA: "NDA207103 SUPPL-20 (Efficacy): submission_status AP, submission_status_date 20250423, review_priority STANDARD; sponsor_name PFIZER; product IBRANCE (PALBOCICLIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207103%22

### late 2025: trial start

- Status: scheduled. Date confidence: half. Stage: 1.
- First seen 2025-11-17, last confirmed 2025-11-21.
- SEC registration statement (S-1) (accession 0001493152-25-024676): "JV is developing palbociclib for injection on the Nano Platform and expects to file the investigational new drug ("IND") and to initiate a Phase 1 trial in late 2025 or early" https://www.sec.gov/Archives/edgar/data/908259/000149315225024676/forms-1.htm
- SEC Form 10-Q (accession 0001493152-25-023834): "JV is developing palbociclib for injection on the Nano Platform and expects to file the investigational new drug ("IND") and to initiate a Phase 1 trial in late 2025 or early" https://www.sec.gov/Archives/edgar/data/908259/000149315225023834/form10-q.htm

### September 16, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA212436 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20250916, review_priority STANDARD; sponsor_name PFIZER; product IBRANCE (PALBOCICLIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212436%22
- openFDA Drugs@FDA: "NDA207103 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20250916, review_priority STANDARD; sponsor_name PFIZER; product IBRANCE (PALBOCICLIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207103%22

### June 5, 2026: PDUFA date

- Status: completed, approved. Date confidence: exact. Stage: 1/2.
- First seen 2025-11-05, last confirmed 2026-02-24.
- SEC Form 10-K (accession 0001628280-26-011226): "•Footnotes included in the graphic above: (a) Includes relapsed/refractory angioimmunoblastic T-cell lymphoma, or AITL, and relapsed/refractory mature B cell NHL; (b) PDUFA date of June 5, 2026; and (c) Phase 1/2 combination clinical trials with palbociclib, atirmociclib, abemaciclib, ribociclib, samuraciclib, everolimus." https://www.sec.gov/Archives/edgar/data/1655759/000162828026011226/arvn-20251231.htm
- SEC Form 10-Q (accession 0001628280-25-049527): "•Footnotes in graphic above: a. Includes relapsed/refractory angioimmunoblastic T-cell lymphoma (AITL) and relapsed/refractory mature B cell NHL; b. Prescription Drug User Fee Act (PDUFA) target action date of June 5, 2026; and c. Phase 1/2 combination trials with palbociclib, atirmociclib, abemaciclib, ribociclib, samuraciclib, everolimus." https://www.sec.gov/Archives/edgar/data/1655759/000162828025049527/arvn-20250930.htm
- openFDA Drugs@FDA: "NDA212436 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20260624, review_priority STANDARD; sponsor_name PFIZER; product IBRANCE (PALBOCICLIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212436%22

### June 24, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA212436 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20260624, review_priority STANDARD; sponsor_name PFIZER; product IBRANCE (PALBOCICLIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212436%22
- openFDA Drugs@FDA: "NDA207103 SUPPL-24 (Efficacy): submission_status AP, submission_status_date 20260624, review_priority STANDARD; sponsor_name PFIZER; product IBRANCE (PALBOCICLIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207103%22

### Dec 2026 to Mar 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05909397 (Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT05909397

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05909397 (Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT05909397

### Jan to Apr 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06760637 (Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-01-02 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT06760637

### January 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06760637 (Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-01-02 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT06760637

### Aug to Nov 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04606446 (Study of PF-07248144 in Advanced or Metastatic Solid Tumors): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-08-27 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT04606446

### August 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04606446 (Study of PF-07248144 in Advanced or Metastatic Solid Tumors): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-08-27 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT04606446

### Dec 2029 to Mar 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Breast Cancer; Head and Neck Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05226871 (Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-12-31 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT05226871

### December 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Breast Cancer; Head and Neck Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05226871 (Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-12-31 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT05226871

## Same indication

- [Piqray (alpelisib)](https://sec-api.dev/pdufa/alpelisib) (NVS)
- [Arm a: gedatolisib + palbociclib + fulvestrant](https://sec-api.dev/pdufa/arm-a-gedatolisib-palbociclib-fulvestrant) (CELC)
- [Truqap (capivasertib)](https://sec-api.dev/pdufa/capivasertib) (AZN)
- [Dato-dxd](https://sec-api.dev/pdufa/dato-dxd) (AZN)
- [Imfinzi® (durvalumab)](https://sec-api.dev/pdufa/durvalumab) (AZN)
- [Revtorpyk (gedatolisib)](https://sec-api.dev/pdufa/gedatolisib) (CELC)
- [Palazestrant](https://sec-api.dev/pdufa/palazestrant) (OLMA)
- [Pcs6422 and capecitabine](https://sec-api.dev/pdufa/pcs6422-and-capecitabine) (PCSA)
- [PF-07220060](https://sec-api.dev/pdufa/pf-07220060) (PFE)
- [PF-07248144](https://sec-api.dev/pdufa/pf-07248144) (PFE)
- [Sv-br-1-gm](https://sec-api.dev/pdufa/sv-br-1-gm) (BCTX)

Calendar months: [December 2026](https://sec-api.dev/fda-calendar/2026-12)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/palbociclib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "IBRANCE® (palbociclib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/palbociclib

```bibtex
@misc{secapidev_pdufa_palbociclib_20261116,
  title        = {IBRANCE® (palbociclib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/palbociclib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_palbociclib_20261116","title":"IBRANCE® (palbociclib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/palbociclib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
